Evolva to transition to new CFO

20. Sep 2016

20 September 2016 – Evolva (SIX: EVE) Evolva announces that its Chief Financial Officer, Jakob Dynnes Hansen, will leave the company for personal reasons. Evolva is in discussion with several suitable external candidates and expects to announce a successor before year-end 2016.

Jakob will stay as CFO until the new candidate is in place, and thereafter support a smooth transition.  Jakob will move to a half time role from November 2016, and is currently expected to depart in Q2 2017. Jakob will return to his native Denmark, taking up a part time position at a young pharma-biotech company.

Jakob has been CFO of Evolva for nine years and played a key role in Evolva’s public listing in 2009 and subsequent public financings. He has also been instrumental in building up the company-wide accounting system and governance structure, which are now both firmly in place.

Evolva Chairman Sir Tom McKillop said “I would like to thank Jakob for his important role in helping move Evolva from a privately held, preclinical biotech to where we are today, with multiple products on market and capabilities across the value chain. We are in discussions with several excellent candidates to help take Evolva through the next stage of our development, and in particular to move us over the next few years to being a cash-flow positive company with a sustainable path to significant revenues and EBITDA.”

Jakob Dynnes Hansen said “This was not an easy decision to take. My nine years with Evolva have been very exciting, but also quite demanding. The time has come for me to rebalance and put my experience to work for younger companies. I am proud to have played my part in getting Evolva to where it is today, and confident the Evolva team has all it takes to achieve great success.”

– ends –

Download Press Release in English

Download Press Release in German

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.

 
Contact Details
Evolva

Neil Goldsmith
CEO
[email protected]
+ 41 61 485 2005
Jakob Dynnes Hansen
CFO
[email protected]
+ 41 61 485 2034
Paul Verbraeken
IR
[email protected]
+ 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

cancel

Sign up to receive our
Press Releases!

Sign up